SynthesisPloS one2012
Use of fibrates and cancer risk: a systematic review and meta-analysis of 17 long-term randomized placebo-controlled trials.
Synthesis in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies.World journal of gastroenterology · 2014Pooled it
- Dyslipidaemias in cancer patients.European heart journal · 2026Review
- The use of cultured human hepatocytes as a test system to evaluate cell proliferation as a key event in nongenotoxic carcinogenesis.Archives of toxicology · 2026Article
- Dose-response effect of statins on colorectal cancer risk in IBD: a nationwide cohort study.BMC cancer · 2026Observational
- The Function of PPARα in Cancer Drug Development: A Promising Target for Cancer Treatment.Current cancer drug targets · 2026Review
- Risk Factors and Prevention of Cancer and CVDs: A Chicken and Egg Situation.Journal of clinical medicine · 2025Review
- Article
- Longitudinal cohort study highlights cancer-preventive benefits of lipid-lowering drugs.iScience · 2024Article
- Lipid-lowering drugs and cancer: an updated perspective.Pharmacological reports : PR · 2024Review
- Total-, LDL-, and HDL-cholesterol, apolipoproteins, and triglycerides with risk of total and fatal prostate cancer in Black and White men in the ARIC study.The Prostate · 2023Article
- Fibrates Affect Levels of Phosphorylated p38 in Intestinal Cells in a Differentiation-Dependent Manner.International journal of molecular sciences · 2023Article
- Metabolic syndrome and thyroid Cancer: risk, prognosis, and mechanism.Discover oncology · 2023Review
- Association between abnormal lipid metabolism and tumor.Frontiers in endocrinology · 2023Review
- Use of Hypolipidemic Drugs and the Risk of Second Primary Malignancy in Colorectal Cancer Patients.Cancers · 2022Article
- Lipoproteins and cancer: The role of HDL-C, LDL-C, and cholesterol-lowering drugs.Biochemical pharmacology · 2022Review
- The Effect of Statins in Cancer Risk Reduction in Patients on Dialysis: A Population-Based Case-Control Study.Journal of clinical medicine · 2021Article
- Review
- Review
- HDL and LDL: Potential New Players in Breast Cancer Development.Journal of clinical medicine · 2019Review
- The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study.PloS one · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibrates comprise a class of well-established antilipidemic agents that significantly reduce cardiovascular events. Given the concerns of cancer with fibrate therapy, we undertook a systematic review and meta-analysis to investigate the effects of fibrates on cancer outcomes.
methodsWe systematically searched Medline, Scopus, SCI Expanded, and the Cochrane Library for studies published up to 2012. We included randomized controlled trials (RCTs) that evaluated a fibrate therapy compared with placebo, had a minimum duration of two years, and reported data on the incidence of and/or deaths from cancer during the trial. Reviews of each study were performed and the relative data were abstracted. Pooled relative risk estimates (RR) and 95% confidence intervals (CIs) were calculated using the inverse variance weighted approach. Subgroup, sensitivity and meta-regression analyses were also conducted.
resultsSeventeen RCTs, involving 44,929 participants with an average follow-up of 5.2 years, contributed to the analysis. The degree of variability between trials was consistent with what would be expected to occur by chance alone. The quantitative synthesis of data retrieved from the RCTs was not indicative of a fibrate effect on cancer incidence (780 [fibrate] vs 814 [control]; RR = 1.02, 95% CI 0.92-1.12) or cancer death (385 [fibrate] vs 377 [control]; RR = 1.06, 95% CI: 0.92-1.22). When the analysis was restricted to major RCTs, the results did not substantially change. Similarly, we found no evidence of differential effects by length of follow-up or type of fibrate. Insignificant results were also obtained for the role of fibrates in cancers of the respiratory tract, breast, colon, gastrointestinal tract, prostate, genitourinary tract, or in melanoma.
conclusionOur findings demonstrate that fibrates have a neutral effect on cancer outcomes. However, it is important to continue monitoring their long-term safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.